This application covers the composition of matter and use of a proprietary placenta derived product that is capable of expanding numerous types of stem cells both outside of the body ( ex vivo) and inside of the body (in vivo). This product is useful as a tissue culture reagent which allows for potent amplification of a patients own stem cells prior to reintroduction into the body. Another in vitro application is the utilization of this product as a research reagent which can be sold to various corporate and academic laboratories. More importantly, the ability of this product to expand stem cells in vivo implies that the major markets of hematopoiesis stimulation post chemotherapy, as well as cosmetic, rejuvenation, and antiaging markets may be addressed.
This patent application covers preparations of a wide variety of stem cells and compositions useful for the treatment of cancer. The stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents.
Transcatheter chemoembolization is clinically used to treat patients with unresectable liver cancer. Our patent application teaches that by addition of a localized immune stimulus to the embolization mixture, we can use the cell death that occurs as a result of this procedure as an “endogenous vaccine” that will stimulate a systemic anti-tumor response. This is based on the fact that immunization in the liver usually results in the induction of a nonproductive immune response, but if appropriate immune stimulators are administered locally, an effective anticancer response will follow that is capable of removing tumor metastasis.
This patent application covers various mechanisms by which stem cell administration can inhibit the progression of valvular dysfunction, including mitral, aortic and semilunar valve regurgitation. The non-surgical regeneration of valve structures is highly desirable in patients that are not suitable to under highly invasive interventions due to age or other factors.
The size of the erectile dysfunction market is tremendous, with approximately 30 million men afflicted in the US. Despite the clinical implementation of phosphodiesterase V inhibitors (e.g. Viagra, Levitra, and Cialis), a significant percentage of patients are not responsive or suffer adverse effects from these approaches. In this patent application methods of using stem cells, and their derivatives are presented for treatment of ED.
The current belief that immune suppression is needed for safety and efficacy of cord blood transplants is overcome by this patent application. The teachings of this patent, which have subsequently been published in the Journal of Translational Medicine, include methods of matching a donor with recipient so as to avoid immune mediated rejection, as well as selectively purifying the graft using clinically approved methods so as to allow for maximal stem cell activity without the need for immune suppression. This patent covers some of the technologies in the AngioStem platform.
Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune Modulation
This patent application provides ways of using stem cells, including adipose tissue mononuclear cells for immune regulation. The technologies in this patent may be used for providing therapeutic solutions to a wide variety of autoimmune diseases, as well as preventing post transplant rejection.
This patent application teaches the use of stem cells for treatment of lower back pain through the stimulation of endogenous biological repair processes. The patent covers several mechanisms, as well as useful cell types and compositions of matter. Back pain costs the U.S. economy over $50 billion annually and represents the second most common reason for visits to a doctor. It is estimated that 10% of 50-year-old discs and 60% of 70-year-old discs are severely degenerated.
This application covers the use of various pharmaceuticals that are currently approved for the mobilization of stem cells to treat autism. The invention is based on the finding that specific compounds such as G-CSF, induce stem cells to exit the bone marrow and enter the blood stream. These stem cells appear to have activity against autism, specifically they suppress various inflammatory reactions that are found in subsets of autistic patients. Additionally, in autism, patients often display a perfusion defect in various areas of the brain such as the temporal lobe. The mobilization of stem cells is used to increase the formation of new blood vessels so as to trigger increased circulation in patients that are identified.
Obesity is associated with numerous physiological abnormalities. In a subset of patients these abnormalities lead to altered metabolism so that even reduction in caloric intake has minimal effect on body mass. This patent application is based on clinical findings that various stem cell populations, especially derived from liposuction mononuclear cells, are capable of inducing weight-loss in subsets of patients.
This patent application covers methods of using menstrual blood as a starting population of cells for isolation of numerous progenitor and stem cell subsets. The application includes various criteria for selection of cells that have specific uses. For example, in some embodiments of the invention cells are selected for high ability to make new blood vessels through isolation of populations having CD9 expression. In other embodiments the cells are selected for ability to differentiate into numerous other lineages, these populations are selected based on expression of c-kit. This application is aimed at covering the composition of matter for the starting cellular population found in the menstrual blood.
This patent application covers specific regenerative cell populations found in the menstrual blood and endometrium. The cell type itself is covered, as well as uses for stimulation of healing either through direct differentiation, anti-inflammatory activity, and/or stimulation of pre-existing endogenous progenitor cells. Numerous conditions may be treated with the cells described in the patent application, these range from autoimmune diseases, to neurodegenerative diseases, to cardiac diseases. This application is of particular interest since a unique cell population is disclosed.
Disclosed are methods and cells useful for the improvement of insulin sensitivity in peripheral tissues. Although it is known that various types of stem cells are useful for the stimulation of insulin production, the concept of using stem cells to increase responsiveness to insulin has not been previously disclosed. The invention teaches that various adult stem cell populations, their supernatants, or various derivatives thereof, are useful for augmenting insulin receptor expression and/or downstream function of signal transduction mechanisms that are associated with insulin resistance. A further embodiment of the invention is that specific types of stem cells can trigger anti-inflammatory responses which in turn increase insulin sensitivity.
The patent application provides various “adjuvants” that are useful for augmenting ability of stem cells to treat cardiovascular disorders. Some of the specific embodiments of the invention are derived from clinical observations of cardiac patients improving after combined administration of stem cells and the agents disclosed. In one embodiment intravenous anti-oxidants are using in combination with systemically delivered mesenchymal stem cells in order to enhance ventricular function.
This patent application covers the treatment of autism through delivery of a population of cells possessing anti-inflammatory effects together with a population capable of stimulating angiogenesis. The invention disclosed provides specific patient subsets that may benefit from administration of stem cells such as mesenchymal and CD34 cells.